AlphAIAlphAI — Financial news for AI agents
tradingview.com

Regeneron Pharmaceuticals SVP Controller Sold Shares Worth Over $3.8M

Regeneron Pharmaceuticals' SVP Controller Jason Pitofsky sold 4,062 shares on November 4, 2026, at $942.21 per share, totaling $3.8M. He now directly owns 4,272 shares and indirectly owns 48 shares. The transaction was disclosed in an SEC Form 4 filing.

Original reporting
tradingview.com
Published Nov 6, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Regeneron Pharmaceuticals SVP Controller Sold Shares Worth Over $3.8M — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The disclosure provides fresh data for traders assessing Regeneron's stock.

02

Market read

First report of a multi‑million dollar insider sell for Regeneron.

03

What to watch

The insider still holds a sizable stake, and the sale size is modest relative to market cap.

Relevance 6/10Novelty 6/10Timing: after‑hours filing

Background

Form 4 filing disclosed the insider transaction.

Market effects

Sector

Minimal impact on the biotech sector; the sale is company‑specific.

Regional

No broader regional effect.

Global

Limited to Regeneron investors.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • executive
    Jason Pitofsky

    SVP Controller of Regeneron Pharmaceuticals

Read at source← All news

Related articles

$LLYHighAI 8/10

Eli Lilly, Regeneron Lead Weight-Loss ETF THNR Higher

Eli Lilly (LLY) and Regeneron (REGN) led gains in the VettaFi Weight Loss Drug & Treatment Index, which rose 3.28% in October. Lilly's Q3 revenue of $24.4B beat estimates, and it raised its 2026 forecast. Regeneron's revenue jumped 36%. AstraZeneca (AZN) and Roche also contributed to the index's gains, while CSPC Pharmaceutical Group and Structure Therapeutics fell.

etfdb.com
HighAI 8/10

Why is Regeneron Pharmaceuticals stock surging today?

Regeneron Pharmaceuticals' stock rose 4.0% to a 52-week high of $972.06 after reporting Q3 2026 earnings of $20.07 per share, up 70% Y/Y, and revenue of $5.116B, up 36% Y/Y. Multiple analysts raised price targets, with BofA Securities at $1,030 and Canaccord Genuity at $1,175. Positive Phase 3 trial data for Libtayo also supported the stock.

investing.com
$REGNMedAI 9/10

Regeneron Stock Jumps 13% to 52-Week High as Sanofi Dupixent Windfall Powers a Blockbuster Third Quarter

Regeneron (REGN) shares rose 13.33% to a 52-week high after reporting Q3 earnings and revenue above expectations, driven by its partnership with Sanofi on Dupixent. Adjusted earnings were $20.07 per share, up 70% YoY, and revenue rose 36% to $5.12 billion. Collaboration revenue from Sanofi reached $2.7 billion, up 68% YoY. The company also expanded its alliance with Sanofi, with a $1 billion upfront payment expected in Q4.

ibtimes.com.au